Breast cancer research and treatment · 2025
Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Amitani Masatsugu, Oba Takaaki, Kitazawa Ayaka, Iji Ryoko, Kiyosawa Nami, Katsuyama Shota, Morikawa Hiroki, Chino Tatsunori, Shimizu Tadafumi, Ono Mayu, Kanai Toshiharu, Ito Ken-Ichi
Аннотация
PURPOSE: In breast cancer, a low skeletal muscle index (SMI) and prognostic nutritional index (PNI) negatively affect patient outcomes. However, the prognostic implications of changes in these values in patients with metastatic breast cancer (MBC) remain unclear. We evaluated the association between baseline levels and changes in SMI and PNI during eribulin treatment and patient outcomes.
METHODS: We retrospectively analyzed 67 patients with MBC treated with eribulin. SMI and PNI were assessed at baseline (pre-SMI, and pre-PNI) and at disease progression; changes from baseline were calculated. Patient outcomes were compared according to baseline status and direction of change.
RESULTS: SMI and PNI were not significantly correlated (p = 0.26, R = 0.02). High pre-SMI and high pre-PNI were associated with significantly improved overall survival (OS) (SMI; hazard ratio [HR] = 0.54, p = 0.04, PNI; HR = 0.33, p < 0.001). Patients with SMI gain during eribulin had longer OS than those with stable SMI or loss (HR = 0.48, p = 0.04), whereas PNI increase was not significantly associated with OS (HR = 0.74, p = 0.32).
CONCLUSION: Baseline SMI and PNI provide complementary prognostic information in patients with MBC receiving eribulin. Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.
METHODS: We retrospectively analyzed 67 patients with MBC treated with eribulin. SMI and PNI were assessed at baseline (pre-SMI, and pre-PNI) and at disease progression; changes from baseline were calculated. Patient outcomes were compared according to baseline status and direction of change.
RESULTS: SMI and PNI were not significantly correlated (p = 0.26, R = 0.02). High pre-SMI and high pre-PNI were associated with significantly improved overall survival (OS) (SMI; hazard ratio [HR] = 0.54, p = 0.04, PNI; HR = 0.33, p < 0.001). Patients with SMI gain during eribulin had longer OS than those with stable SMI or loss (HR = 0.48, p = 0.04), whereas PNI increase was not significantly associated with OS (HR = 0.74, p = 0.32).
CONCLUSION: Baseline SMI and PNI provide complementary prognostic information in patients with MBC receiving eribulin. Furthermore, on-treatment SMI gain, but not PNI increase, was associated with improved survival. Monitoring and enhancing skeletal muscle mass may improve outcomes, highlighting the importance of integrating supportive care strategies during chemotherapy.